Xcell Therapeutics Inc. (KOSDAQ:373110)

Xcell Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,355	7,764	1,239	5,436	14,632	6,662
Short-Term Investments	300	35.67	120	120	-	8
Trading Asset Securities	-	1,002	-	-	-	-
Cash & Short-Term Investments	3,655	8,802	1,359	5,556	14,632	6,670
Cash Growth	4495.30%	547.78%	-75.55%	-62.03%	119.39%	701.34%
Accounts Receivable	113.15	54.71	282.87	264.4	159.42	26.28
Other Receivables	-	455.24	333.93	368.52	109.59	384.62
Receivables	113.15	509.96	616.8	632.92	269.01	410.9
Inventory	936.98	697.92	804.25	686.9	500.67	680.19
Prepaid Expenses	-	10.6	-	-	-	-
Other Current Assets	665.66	491.19	60.41	339.89	22.45	6.22
Total Current Assets	5,371	10,512	2,840	7,216	15,425	7,767
Property, Plant & Equipment	4,680	4,472	5,355	7,372	7,515	5,773
Long-Term Investments	1,130	1,099	34.78	31.69	19.81	7.93
Other Intangible Assets	657.04	537.35	125.05	307.51	238.75	247.1
Long-Term Accounts Receivable	0	-0	-0	-0	-0	0
Other Long-Term Assets	261.76	269.81	2,113	582.39	503.45	273.4
Total Assets	12,100	16,890	10,468	15,509	23,702	14,068
Accounts Payable	131.39	125.57	133.66	90	227.29	464.82
Accrued Expenses	359.88	295.36	263.38	277.52	244.79	234.77
Short-Term Debt	3,500	3,500	4,000	4,000	4,000	1,400
Current Portion of Long-Term Debt	116.64	87.56	72.5	-	-	20
Current Portion of Leases	543.62	465.62	589.68	449.1	453.31	413.96
Other Current Liabilities	496.68	432.39	383.32	370.56	332.31	3,483
Total Current Liabilities	5,148	4,906	5,443	5,187	5,258	6,017
Long-Term Debt	1,074	1,132	1,148	870	870	2,821
Long-Term Leases	421.5	515.99	695.9	527.77	868.12	252.73
Other Long-Term Liabilities	522.61	520.26	510.64	440.67	387.31	3,188
Total Liabilities	8,051	7,769	8,085	7,026	7,477	12,683
Common Stock	5,469	5,459	4,582	4,380	4,376	1,494
Additional Paid-In Capital	58,108	57,993	42,711	39,913	39,860	18,153
Retained Earnings	-60,992	-55,717	-46,071	-36,835	-28,407	-19,358
Comprehensive Income & Other	1,463	1,386	1,162	1,025	395.85	342.59
Total Common Equity	4,049	9,121	2,384	8,483	16,225	632.37
Shareholders' Equity	4,049	9,121	2,384	8,483	16,225	1,385
Total Liabilities & Equity	12,100	16,890	10,468	15,509	23,702	14,068
Total Debt	5,656	5,702	6,506	5,847	6,191	4,907
Net Cash (Debt)	-2,000	3,100	-5,147	-290.75	8,441	1,762
Net Cash Growth	-	-	-	-	378.96%	-
Net Cash Per Share	-183.65	309.85	-581.98	-33.21	1019.25	491.75
Filing Date Shares Outstanding	10.94	10.92	9.16	8.76	8.28	2.99
Total Common Shares Outstanding	10.94	10.92	9.16	8.76	8.28	2.99
Working Capital	223.04	5,605	-2,602	2,029	10,167	1,750
Book Value Per Share	370.12	835.38	260.10	968.50	1959.16	211.63
Tangible Book Value	3,391	8,584	2,258	8,176	15,986	385.27
Tangible Book Value Per Share	310.05	786.16	246.46	933.39	1930.33	128.94
Land	370.53	370.53	370.53	1,971	1,971	1,971
Buildings	1,283	1,624	1,624	1,624	1,624	1,624
Machinery	1,320	3,320	3,059	2,952	2,433	2,107
Construction In Progress	-	-	-	-	278.4	0.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.